Advanced Search
Disease Phase
Title Drug
Clinical Trials Listing
  • < Previous
  • 1
  • Next >
  • Penn Treatment Trials (12)
  • Penn Non-Treatment Trials (9)
  • Phase 1: Solid Tumor Trials (0)
  • Proton Therapy Trials (0)
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
715 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients With Hematologic Malignancies (BMT CTN #1101) III Immunotherapy Not Applicable
UPCC-29412 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas III Immunotherapy, Signal Transduction Inhibitor rituximab; Idelalisib
UPCC-03712 Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients with Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL) II Immunotherapy CART 19
CR100956 An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma II Signal Transduction Inhibitor ibrutinib
ECOG-E1A10 A Randomized Phase I/II Study of Bortezomib, Rituximab, Dexamethasone and Temsirolimus in Patients With Relapsed Waldenstrom's Macroglobulinemia and Relapsed/Refractory Mantle Cell, Follicular, Marginal Zone or Small Lymphocytic Lymphomas (Phase I), and Untreated/Relapsed Waldenstrom's Macroglobulinemia (Phase II) I / II Hormonal Therapy, Immunotherapy, Signal Transduction Inhibitor bortezomib; rituximab; dexamethasone; temsirolimus
UPCC 11411 Maintenance Lenalidomide in Lymphoma I / II Immunotherapy lenalidomide
UPCC 03411 A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma I / II Immunotherapy resiquimod
813320 A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma I / II Immunotherapy resiquimod
CHP959 Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma I Immunotherapy CART 19
UPCC 04409 Pilot Study of Redirected Autologous Tcells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patient With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma I Biological Therapy, Chemotherapy CD19CAR T-cells
UPCC 24412 A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy I Immunotherapy BMS-936558
UPCC-18406 A Phase I Study of Bexxar&reg; (Tositumomab and 131I-Tositumomab) Radioimmunotherapy in Patients With Relapsed or Residual CD20 Antigen-Expressing B-Cell Lymphomas Following Autologous Hematopoietic Stem Cell Transplantation I Bone Marrow Transplant / Stem Cell Transplant, Radiotherapy, Immunotherapy tositumomab
Displaying: 1 - 12 of 12 Results
  • < Previous
  • 1
  • Next >